Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|May 17, 2023

Avirmax Opens New Gene Therapy Facility

Author(s)Grant Playter

Avirmax’s new gene therapy facility in Hayward, Calif., will specialize in AAV gene therapy research and development.

Avirmax, a biopharmaceutical company specializing in recombinant adeno-associated virus (rAAV) vector-mediated biotherapeutics, has launched its new outsourcing facility in Hayward, Calif. on May 11, 2023. The facility, intended for contract development and manufacturing services, will specialize in AAV gene therapy research and development.

According to a May 15, 2023 press release, the facility is 20,000 ft² and contains current good manufacturing practice suites, as well as developmental and testing laboratories. The facility is equipped with single-use bioreactors at 50-L, 200-L, and 1000-L production scales. According to the release, it can deliver rAAV drug product at 1016-18 vector genome per batch within approximately 200 days starting from a transgene DNA plasmid.

"Your business will complement the STEM [science, technology, engineering, and math] Centers of the middle and high schools, and when students graduate and are looking for jobs, we will send them here first," said Mark Salinas, mayor, Hayward, in an inauguration speech held for the facility.

Source: Avirmax


Related to this article

The BioPharm Brief: Long-Term Survival Data for a PD-L1/4-1BB Bispecific, Celldex Exits Atopic Dermatitis, and a Fc-Fusion GLP-1 Goes Global
Leads Biolabs details survival data and 2027 ADC combination plans for its PD-L1/4-1BB bispecific opamtistomig, Celldex Therapeutics ends its atopic dermatitis program for anti-KIT antibody barzolvolimab after a phase 2 miss, and Innogen licenses its Fc-fusion GLP-1 receptor agonist efsubaglutide alfa to Arcera Life Sciences for international markets.
The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron’s cemdisiran (Livsayis), an RNAi therapy Regeneron licensed from Alnylam Pharmaceuticals, as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.